source
- Roche signs near-$1 billion partnership with Chinese biotech Defand on degrader therapiesRoche has entered into a new collaboration with Defand, a relatively unknown biotech based in Hangzhou, China. The agreement is the fourth China-focused deal the Swiss drugmaker has signed since Au…
- Congressional Bill Aims to End Arbitration in No Surprises Act, Shifting Payments to Median In-Network RatesRep. Frank Pallone introduced the Lower Premiums, Faster Payments Act, which would eliminate the arbitration system used under the No Surprises Act and replace it with a payment model based on medi…